logo
Plus   Neg
Share
Email

Novartis: Sandoz To Commercialize OIC Drug Rizmoic In Key European Countries

Swiss drug major Novartis AG (NVS) announced Thursday that Sandoz has signed an agreement with Japanese pharmaceutical company Shionogi & Co Ltd for commercialization of Rizmoic (naldemedine) in the key European markets of Germany, the UK and the Netherlands, plus right of first refusal for certain other European markets.

Under the terms of the agreement, Sandoz will be responsible for commercializing Rizmoic in Germany, the UK and the Netherlands and Shionogi will be responsible for its manufacturing and development. Further details of the deal are not being disclosed.

Rizmoic, a once-daily 200-microgram oral tablet discovered and developed by Shionogi, is an innovative medicine indicated to treat opioid induced constipation or OIC in adult patients previously treated with a laxative. OIC is a prevalent and distressing side-effect of opioid therapy that does not respond reliably to treatment with conventional laxatives.

Shionogi announced on February 22, 2019 that it had received EU marketing authorization for Rizmoic.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Target Corp. has introduced Everspring, a new household essentials brand comprised of more than 70 household essentials items that includes bio-based or recycled materials or natural fibers. The new, in-house brand has been designed by Target with sustainability in mind and is part of its efforts to make products that include ingredients derived from plants or renewable materials more accessible. While reporting financial results for the first quarter, American Express Co. (AXP) on Thursday affirmed its earnings and revenue growth guidance for the full-year 2019. For fiscal 2019, the company continues to project earnings in the range of $7.64 to $8.14 per share and adjusted earnings in the... While reporting financial results for the first quarter, Honeywell international Inc. (HON) on Thursday raised its earnings and sales outlook for the full-year 2019. For fiscal 2019, the company raised its earnings outlook to a range of $7.90 to $8.15 per share from the previous guidance range of...
Follow RTT